Quantitative analysis for Spero Therapeutics, Inc. (SPRO) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Unrated (50.0). 26 signals analyzed (23 differentiated alt-data).
SPRO stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $2.73 | $2.67 | $2.67 |
| 2026-05-08 | $2.58 | $2.49 | $2.56 |
| 2026-05-20 | $2.65 | $2.55 | $2.63 |
| 2026-06-02 | $2.87 | $2.76 | $2.83 |
| 2026-06-12 | $2.85 | $2.70 | $2.85 |
| 2026-06-25 | $2.13 | $2.02 | $2.02 |
| 2026-07-08 | $2.23 | $2.13 | $2.17 |
| 2026-07-20 | $1.57 | $1.41 | $1.44 |
| 2026-07-30 | $1.22 | $1.17 | $1.20 |
| 2026-08-12 | $1.25 | $1.18 | $1.19 |
| 2026-08-24 | $1.24 | $1.20 | $1.22 |
| 2026-09-03 | $1.23 | $1.20 | $1.22 |
How Spero Therapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| ASRT | Assertio Holdings, Inc. | $151M | — |
| PRQR | ProQR Therapeutics N.V. | $151M | — |
| OGI | Organigram Global Inc. | $151M | — |
| VXRT | Vaxart, Inc. | $148M | — |
View all Health Care stocks by valuation and signals →
Spero Therapeutics, Inc. (SPRO) scores Unrated (50.0), and the composite conceals a 66-point disagreement between its dimensions. It is strongest on analyst consensus at 67, and weakest on technicals at 2 and competitive moat at 1. A stock can carry analyst consensus that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 67 |
| technicals | 2 |
| competitive moat | 1 |
StoQuant analyzes 26 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Spero Therapeutics, Inc. (SPRO): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/SPRO"><img src="https://stoquant.com/badge/SPRO.svg" alt="Spero Therapeutics, Inc. (SPRO) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.